Intracellular delivery with microfluidic vortex shedding (µVS)
Our microfluidic gene delivery platform can be used for gentle, scalable, and viral-free delivery of a range of molecules to several cell types, including human primary immune cells. Our team works with you to verify our platform for your specific applications.
|Info||Device||Proof of Concept||Optimization|
|PMBCs or T cells|
|mRNA||Toggle more info||85%|
We demonstrate efficient mRNA expression of enhanced green fluorescent protein (EGFP) (e.g., 57.4 ± 6.8% of viable, recovery cells, mean ± stdev) after mRNA delivery to primary human T cells with high cell viability (e.g., 83.7 ± 0.7% of recovered cells), high cell recovery (e.g., 96.3 ± 1.1% of processed cells), and minimal alteration to T cell activation profile.
|Cas9 RNPs (CRISPR)||Toggle more info||60%|
We are currently delivering Cas9 RNP complex to knock out and modify functional T cell markers. Please contact us for more information.
|Plasmids||Toggle more info||55%|
We currently performing a delivery screen of plasmids ranging from 2-10kb into human primary T cells. In addition, we are developing a non-viral method for stable and persistent gene modification. Get in touch for more information.